Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

HTG Molecular Diagnostics, Inc. (HTGM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.3900+0.1100 (+3.35%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close3.2800
Open3.3800
Bid3.3400 x 1200
Ask3.4000 x 3100
Day's Range3.2800 - 3.4300
52 Week Range3.2000 - 7.9500
Volume54,707
Avg. Volume29,382
Market Cap25.655M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-2.5800
Earnings DateNov 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HTGM

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • HTG Molecular Diagnostics, Inc.
    Analyst Report: Guardant Health, Inc.Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • GlobeNewswire

    HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration

    HTG’s Innovative Transcriptome Panel Technology to be Leveraged in Retrospective StudiesTUCSON, Ariz., Nov. 17, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, and the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai), world-renowned for its groundbreaking research, announced they have entered into a new research collaboration as part of HTG

  • GlobeNewswire

    HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    TUCSON, Ariz., Nov. 15, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that, on November 9, 2021 the Compensation Committee of the HTG Board of Directors granted inducement stock option awards to purchase an aggregate of 80,000 shares of common stock and 30,000 restricted stock unit awards (RSUs) to two employees who have recently joi

  • GlobeNewswire

    HTG Molecular Diagnostics Reports Third Quarter 2021 Results

    Call scheduled for today, November 10, at 4:30 pm ETTUCSON, Ariz., Nov. 10, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its financial results for the quarter ended September 30, 2021. Recent Business Highlights Total revenue for the quarter ended September 30, 2021 increased by approximately 42% when compared to the same period in 2

Advertisement
Advertisement